Retatruide

What is Retatrutide?

Retatrutide is an investigational medication being developed by Eli Lilly for the treatment of obesity and weight-related health conditions. It belongs to a new generation of metabolic therapies designed to support weight management through multiple biological pathways involved in appetite regulation, energy balance and metabolism.

Early clinical studies have generated significant interest within the medical community due to the substantial weight loss observed in trial participants.

How Does Retatrutide Work?

Unlike current weight management medications that target one or two hormone receptors, Retatrutide is designed to activate three separate receptors:

• GLP-1 receptor — helps regulate appetite and food intake by increasing feelings of fullness and reducing hunger.
• GIP receptor — supports insulin regulation and may enhance the body's response to GLP-1 therapy.
• Glucagon receptor — may increase energy expenditure and influence fat metabolism.

This combination of three pathways is why Retatrutide is often referred to as a "triple agonist."

Retatrutide vs Other Weight Loss Medications

Retatrutide is currently the only therapy in development that combines all three pathways.

Important Information

Retatrutide is currently an investigational medication and has not been approved for prescribing in the United Kingdom. Any information provided about Retatrutide is for educational purposes only and should not be considered medical advice or a recommendation for treatment.

Retatrutide is currently undergoing late-stage clinical trials, with regulatory submissions expected following completion of these studies. If approved, it may become available in the UK in the coming years, although no official launch date has been confirmed. Patients interested in future developments are encouraged to follow updates from regulatory authorities and healthcare professionals.